SCHEMBL2086487

SCHEMBL2086487

Cc1cnc(CNCc2ncccc2C(C)C)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.38
PIP4K2C Q8TBX8 1/20 0.36
USP1 O94782 4/20 0.34
WDR48 Q8TAF3 4/20 0.34
CCR1 P32246 1/20 0.34
CCR5 P51681 1/20 0.34
CCR8 P51685 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ADORA2A P29274 2/20 0.33
PIP4K2A P48426 1/20 0.33
ACHE P22303 1/20 0.33
ADRB2 P07550 1/20 0.33
ALPL P05186 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
ADORA1 P30542 1/20 0.31
SLC40A1 Q9NP59 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2085284 0.86 MAOA (0.40) CXCR4PIP4K2CUSP1WDR48ADORA2A
SCHEMBL5574543 0.82 CXCR4 (0.36) CXCR4PIP4K2CUSP1WDR48
SCHEMBL2084718 0.81 CXCR4 (0.41) CXCR4ALDH1A1
SCHEMBL2082339 0.78 ADORA2A (0.42) ADORA2AALDH1A1ADORA1
SCHEMBL2082894 0.78 CXCR4 (0.42) CXCR4SLC6A2SLC6A4SLC6A3ADRB2
SCHEMBL4560383 0.75 CXCR4 (0.38) CXCR4PIP4K2CCCR1CCR5CCR8
SCHEMBL4033313 0.74 CXCR4 (0.49) CXCR4SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL2084491 0.74 CNR2 (0.40) CXCR4ALDH1A1
SCHEMBL2083387 0.74 CXCR4 (0.45) CXCR4
SCHEMBL23428604 0.73 CXCR4 (0.46) CXCR4SLC6A2SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 CXCR4 1/4885PIP4K2C 4234/4885USP1 3648/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 CXCR4 1/4885PIP4K2C 3843/4885USP1 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.